The linker matters in antibody-drug conjugates
Interviewee/Contributor
Philipp Spycher
Organisation
Araris Biotech AG
Antibody Drug Conjugates ADCs
The US continues to lead in oncology approvals
Interviewee/Contributor
Bruno Pagliara
Organisation
MedNous
Revisiting antibody-drug conjugates
Interviewee/Contributor
Chris Martin
Organisation
ADC Therapeutics SA
Targeting new medicines at Roche
Interviewee/Contributor
Max Hasmann
Organisation
Roche Group
The inventive step: antibody-drug conjugates
Interviewee/Contributor
John Lambert
Organisation
ImmunoGen Inc
Antibodies and ADCs lead cancer pipeline
Interviewee/Contributor
Bruno Pagliara
Organisation
On-Kos Pharma Consulting
ADCs propelled back into the oncology spotlight
Interviewee/Contributor
Karen Finn
Organisation
MedNous
Why Oxford BioTherapeutics is targeting ADCs
Interviewee/Contributor
Christian Rohlff
Organisation
Oxford BioTherapeutics Ltd
How developers approach antibody drug conjugates
Interviewee/Contributor
Bruno Pagliara
Organisation
On-kòs Pharma Consulting